Larimar Therapeutics shares long-term OLE study data on nomlabofusp, showing increased FXN levels in Friedreich’s Ataxia patients and well-tolerated treatment.
Why Is Larimar Therapeutics Stock Trading Lower On Monday?
Where Today's News Shapes Tomorrow
